Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide
and sitagliptin by using continuous glucose monitoring: a pilot study.
Author(s): Ando K(1), Nishimura R, Seo C, Tsujino D, Sakamoto M, Utsunomiya K.
Affiliation(s): Author information:
(1)Jikei University School of Medicine, Division of Diabetes, Metabolism and
Endocrinology, Department of Internal Medicine , 3-19-18 Nishishimbashi,
Minato-ku, Tokyo 105-8471 , Japan rimei@jikei.ac.jp.
Publication date & source: 2014, Expert Opin Pharmacother. , 15(17):2479-85
OBJECTIVE: To compare postprandial efficacy in type 2 diabetic patients given
mitiglinide and sitagliptin, both of which are known to improve postprandial
hyperglycemia, by using continuous glucose monitoring (CGM).
METHODS: Eleven patients with type 2 diabetes were given mitiglinide 10 mg three
times a daily or sitagliptin 50 mg once a day for 1 month and were hospitalized
for 4 days and evaluated by CGM. On discharge, they were crossed over to the
other regimen for 1 month of treatment/4 days of evaluation. The CGM data were
used to compare each parameter for glycemic variability.
RESULTS: The patients were 60 ± 10 (mean ± SD) years old, and had HbA1c value 7.3
± 0.9%. The pre-meal glucose levels before lunch were significantly lower with
mitiglinide than with sitagliptin (116 ± 26/131 ± 34 mg/dl, p = 0.022). The AUC
measuring over 140 mg/dl 3 h after breakfast (mitiglinide 4812 ± 4219/sitagliptin
7807 ± 6391 mg/dl·min, p = 0.042) and lunch (mitiglinide 5658 ± 5856/sitagliptin
8492 ± 7161, p = 0.050) was significantly lower with mitiglinide than with
sitagliptin.
CONCLUSIONS: A CGM-based comparison showed that mitiglinide and sitagliptin were
different in their glucose-lowering effects, where mitiglinide significantly
improved hyperglycemia after breakfast and lunch, and significantly lowered
pre-meal glucose levels before lunch, compared to sitagliptin.
|